Homology Medicines, Inc. (FIXX): Price and Financial Metrics
FIXX Price/Volume Stats
| Current price | $1.17 | 52-week high | $2.29 |
| Prev. close | $1.17 | 52-week low | $0.80 |
| Day low | $1.14 | Volume | 121,300 |
| Day high | $1.19 | Avg. volume | 203,639 |
| 50-day MA | $1.17 | Dividend yield | N/A |
| 200-day MA | $1.19 | Market Cap | 67.64M |
FIXX Stock Price Chart Interactive Chart >
FIXX POWR Grades
- FIXX scores best on the Sentiment dimension, with a Sentiment rank ahead of 58.54% of US stocks.
- FIXX's strongest trending metric is Value; it's been moving down over the last 179 days.
- FIXX ranks lowest in Momentum; there it ranks in the 16th percentile.
FIXX Stock Summary
- FIXX's price/sales ratio is 25.14; that's higher than the P/S ratio of 95.09% of US stocks.
- Over the past twelve months, FIXX has reported earnings growth of 42,090.42%, putting it ahead of 100% of US stocks in our set.
- As for revenue growth, note that FIXX's revenue has grown -32.4% over the past 12 months; that beats the revenue growth of merely 8.16% of US companies in our set.
- Stocks that are quantitatively similar to FIXX, based on their financial statements, market capitalization, and price volatility, are INSW, CPTN, TOI, RXT, and IIIV.
- Visit FIXX's SEC page to see the company's official filings. To visit the company's web site, go to www.homologymedicines.com.
FIXX Valuation Summary
- FIXX's price/sales ratio is 25.1; this is 527.5% higher than that of the median Healthcare stock.
- FIXX's price/sales ratio has moved NA NA over the prior 67 months.
Below are key valuation metrics over time for FIXX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FIXX | 2023-09-18 | 25.1 | 0.6 | -0.5 | -0.2 |
| FIXX | 2023-09-15 | 24.5 | 0.6 | -0.5 | -0.1 |
| FIXX | 2023-09-14 | 24.7 | 0.6 | -0.5 | -0.2 |
| FIXX | 2023-09-13 | 24.5 | 0.6 | -0.5 | -0.1 |
| FIXX | 2023-09-12 | 24.5 | 0.6 | -0.5 | -0.1 |
| FIXX | 2023-09-11 | 24.5 | 0.6 | -0.5 | -0.1 |
FIXX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FIXX has a Quality Grade of D, ranking ahead of 17.28% of graded US stocks.
- FIXX's asset turnover comes in at 0.134 -- ranking 233rd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FIXX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.134 | 1 | -1.031 |
| 2021-03-31 | 0.128 | 1 | -1.267 |
| 2020-12-31 | 0.010 | 1 | -1.629 |
| 2020-09-30 | 0.008 | 1 | -0.944 |
| 2020-06-30 | 0.007 | 1 | -0.719 |
| 2020-03-31 | 0.006 | 1 | -0.566 |
FIXX Price Target
For more insight on analysts targets of FIXX, see our FIXX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.20 | Average Broker Recommendation | 1.32 (Strong Buy) |
Homology Medicines, Inc. (FIXX) Company Bio
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.
Latest FIXX News From Around the Web
Below are the latest news stories about HOMOLOGY MEDICINES INC that investors may wish to consider to help them evaluate FIXX as an investment opportunity.
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates. “We recently shared the encouraging initial data from the |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday! |
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKUAnnounced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial Evaluating HMI-103 BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. Earlier today, Homology reported encouraging initial data from the first dose level in the Phas |
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKUParticipant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L)*; At 31 Weeks Post-Dose, Phe Level 319 μmol/L With a 59% Reduction from Baseline, Even After Dietary Protein Supplementation Participant 2 Plasma Phe Level Reduction of 49% Change from Baseline at 17 Weeks Post-Dose HMI-103 Has Been Generally Well-Tolerated Webcast Scheduled for Today, July 27, 2023 at 4:30 p.m. ET BEDFORD, Mass |
12 Best Nano Cap Stocks To Buy NowIn this piece, we will take a look at the 12 best nano cap stocks to buy now. If you want to skip our analysis of the current market environment, some nano cap companies doing good work, and want to jump ahead to the top five stocks in this piece, then take a look at […] |
FIXX Price Returns
| 1-mo | -1.68% |
| 3-mo | 31.88% |
| 6-mo | 23.16% |
| 1-year | -24.52% |
| 3-year | -89.11% |
| 5-year | -94.88% |
| YTD | -7.14% |
| 2022 | -65.38% |
| 2021 | -67.76% |
| 2020 | -45.46% |
| 2019 | -7.42% |
| 2018 | N/A |
Continue Researching FIXX
Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...